The major factors driving the growth of the chronic kidney disease treatment industry include rise in R&D activities for the launch of novel drugs and improvement in existing drugs. Moreover, the rise in the number of approvals from government regulatory institutes is creating lucrative opportunities for the chronic kidney disease treatment market. For instance, in April 2021, AstraZeneca, a global leading life science company, received approval from the U.S. FDA for Farxiga, a prescription medicine approved to reduce the risk of further worsening of initial stage kidney disease to end-stage kidney disease. In addition.
Know More- https://www.alliedmarketresearch.com/chronic-kidney-disease-treatment-market-A107121
